Antibiogram Surveillance to Determine Appropriate Initial Empiric Antibiotic Therapy for Ventilator-Associated Pneumonia
Surgical Infections · 2025
DOI: 10.1089/sur.2024.256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgical Infections, 2025. Verfasst von Andrew J Kerwin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Trauma and Surgical Critical Care, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Pneumonia, Ventilator-Associated, Anti-Bacterial Agents, Bacteria. Die Arbeit nennt 25 Literaturangaben.
Themen: Pneumonieprophylaxe
Abstract (Originalsprache)
Background
Our protocolized empiric antibiotic therapy for early (≤7 d) ventilator-associated pneumonia (VAP) and late (>7 d) VAP based on our local antibiogram leads to inappropriate empiric antibiotic therapy (IEAT) approximately 15% of the time. We reviewed our trauma intensive care unit (TICU) antibiogram to determine if sensitivity patterns were changing and warranted protocol adjustments. We hypothesized there would be no change in IEAT over time. Patients and Methods: TICU patients with VAP (bronchoalveolar lavage culture ≥100,000 CFU/mL) between 2017 and 2022 were reviewed. We reviewed the pathogens and sensitivity patterns to identify the IEAT percentage, and we reviewed changes in the rate of antimicrobial days per 1,000 days present for 2018-2022.
Results
We noted an increase in IEAT beginning in 2017. In early VAP, the increase in IEAT was because of an increase in identification of gram-negative bacteria isolates (7%-24%), specifically an increase in Pseudomonas (3%-10%) and a decrease in Streptococcus sp. (32%-23%) and Haemophilus influenzae (20%-17%). In late VAP, the increase in IEAT was largely because of an increase in identification of Stenotrophomonas (3%-5%) and Acinetobacter (4%-10%). Antimicrobial use changed as pathogens and sensitivity changed. There were increases in rates per 1,000 days for cefazolin (11.9%), vancomycin (22.8%), cefepime (33.1%), and meropenem (424.7%), whereas there were decreases in rates per 1,000 days for ampicillin/sulbactam (-4.5%) and piperacillin/tazobactam (-9.5%).
Conclusions
The change in organisms identified and the increase in IEAT highlight the importance of continuous antibiogram monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Trauma and Surgical Critical Care, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Regional One Health, Memphis, Tennessee, USA.
Zitieren
APA
Kerwin, A. J., Wood, G. C., Byerly, S., Filiberto, D. M., Farrar, J. E., Swanson, J. M., Rogers, M. L., & Croce, M. A. (2025). Antibiogram Surveillance to Determine Appropriate Initial Empiric Antibiotic Therapy for Ventilator-Associated Pneumonia. Surgical Infections. https://doi.org/10.1089/sur.2024.256
Vancouver
Kerwin AJ, Wood GC, Byerly S, Filiberto DM, Farrar JE, Swanson JM, et al. Antibiogram Surveillance to Determine Appropriate Initial Empiric Antibiotic Therapy for Ventilator-Associated Pneumonia. Surgical Infections. 2025. doi:10.1089/sur.2024.256
BibTeX
@article{Kerwin2025,
author = {Kerwin, Andrew J and Wood, G Christopher and Byerly, Saskya and Filiberto, Dina M and Farrar, Julie E and Swanson, Joseph M and Rogers, Maegan L and Croce, Martin A},
title = {Antibiogram Surveillance to Determine Appropriate Initial Empiric Antibiotic Therapy for Ventilator-Associated Pneumonia},
journal = {Surgical Infections},
year = {2025},
doi = {10.1089/sur.2024.256}
}
EUVIMED